Related Experiment Video
Updated: May 12, 2026
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
GDF10 exacerbates metastatic burden and cachexia in murine models of cancer
Lauren S James1, Alastair A E Saunders1, Chris Karagiannis1
1Centre for Muscle Research, and Department of Anatomy and Physiology, The University of Melbourne, Parkville, VIC, Australia.
Abstract:
Metastasis and cancer-induced cachexia significantly reduce survivorship and quality of life for cancer patients. GDF10 (BMP3b) is a TGF-ß superfamily ligand with little knowledge of its role in cancer progression. Some studies have shown that GDF10 exerts tumor-suppressive effects in a range of cancer types and also plays a protective role against muscle wasting. Basal transcription of GDF10 was described previously to be downregulated in both primary tumors and cachectic muscle. Here, we set out to investigate the therapeutic potential of GDF10 in the 4T1.2 mouse model of breast cancer metastasis and in the C-26 mouse model of cancer cachexia, hypothesizing that GDF10 would ameliorate both metastatic and cachectic disease pathology. Systemic rAAV6:GDF10 administration to mice did not alter primary tumor growth; however, metastatic burden was increased in the mice bearing 4T1.2 tumors. Similarly, increased intramuscular rAAV6:GDF10 expression exacerbated skeletal muscle wasting in C-26 tumor-bearing mice. These results contradicted our initial hypothesis and highlight the complexity of signaling mechanisms utilized by BMP family ligands. Our data point to the need for more research to understand how to target GDF10 in anti-cancer therapy.
Insights
Investigating growth differentiation factor 10 (GDF10) for cancer therapy, this study found that GDF10 administration unexpectedly increased metastasis and muscle wasting in mouse models. Further research is needed to understand GDF10
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Metastasis and cancer cachexia severely impact cancer patient survival and quality of life.
- Growth differentiation factor 10 (GDF10), a TGF-ß superfamily ligand, has shown potential tumor-suppressive and anti-cachexia effects in prior studies.
- GDF10 expression is often downregulated in primary tumors and cachectic muscle.
Purpose of the Study:
- To evaluate the therapeutic potential of GDF10 in mouse models of breast cancer metastasis (4T1.2) and cancer cachexia (C-26).
- To test the hypothesis that GDF10 administration would reduce metastatic burden and ameliorate cachectic pathology.
Main Methods:
- Systemic administration of adeno-associated virus serotype 6 carrying GDF10 (rAAV6:GDF10) in 4T1.2 and C-26 mouse models.
- Assessment of primary tumor growth, metastatic burden, and skeletal muscle wasting.
Main Results:
- Systemic rAAV6:GDF10 did not affect primary tumor growth in the 4T1.2 model.
- Increased metastatic burden was observed in 4T1.2 tumor-bearing mice treated with rAAV6:GDF10.
- Intramuscular rAAV6:GDF10 exacerbated skeletal muscle wasting in C-26 tumor-bearing mice.
Conclusions:
- The results contradict the initial hypothesis, indicating GDF10 may promote rather than inhibit cancer progression and cachexia in these models.
- The complex signaling of Bone Morphogenetic Protein (BMP) family ligands necessitates further investigation for effective anti-cancer therapeutic targeting.
- More research is required to elucidate the precise role of GDF10 in cancer and to determine its viability as a therapeutic target.
